Выходит 6 номеров в год
ISSN Печать: 1040-8401
ISSN Онлайн: 2162-6472
Indexed in
Cellular Mucins: Targets for Immunotherapy
Краткое описание
Mucins are attracting great interest as potential targets for immunotherapy in the development of vaccines for cancers expressing Mucinl (MUC1) (e.g., breast, pancreas, ovary, and others) as there is (1) a 10-fold increase in the amount in adenocarcinomas; (2) an alteration in expression where they become ubiquitous, and (3) due to altered glycosylation, new epitopes appear on the cell surface that are absent in normal tissues. These new epitopes can be carbohydrate; others are peptide in nature. The cloning of the cDNAs from mucins, particularly MUC1, has led to rapid advances being made, and it is clear that a highly immunogenic peptide exists within the variable number of tandem repeats (VNTR) found in all mucins. This peptide is immunogenic in mice, giving rise to strong antibody production, and most monoclonal antibodies made to breast cancer, which react with the protein core, react with the peptide APDTR. It is now also clear that humans with breast cancer have, in their draining lymph nodes, precursors of cytotoxic T cells that can be stimulated in vitro to react against breast cancer and indeed against the APDTR or a closely related peptide − shown from antibody-blocking studies. These CTLs are unique in that they are non-MHC restricted. The identification of suitable targets, coupled with the known immunogenicity of both the peptide and neo-carbohydrate epitopes, has led to the development of several different programs to immunize humans against breast cancer using either synthetic carbohydrates or peptides conjugated with adjuvants, and clinical trials are now in progress to evaluate their immunogenicity and anti-cancer effects.
-
Laheru Dan, Jaffee Elizabeth M., Immunotherapy for pancreatic cancer — science driving clinical progress, Nature Reviews Cancer, 5, 6, 2005. Crossref
-
Melero José A., Molecular Biology of Human Respiratory Syncytial Virus, in Respiratory Syncytial Virus, 14, 2006. Crossref
-
Sotiriadis John, Shin Soon-Cheon, Yim Daesong, Sieber David, Kim Yoon Berm, Thomsen-Friedenreich (T) antigen expression increases sensitivity of natural killer cell lysis of cancer cells, International Journal of Cancer, 111, 3, 2004. Crossref
-
Pouniotis Dodie S., Apostolopoulos Vasso, Pietersz Geoffrey A., Penetratin tandemly linked to a CTL peptide induces anti-tumour T-cell responses via a cross-presentation pathway, Immunology, 117, 3, 2006. Crossref
-
Barrett John, Childs Richard, The Benefits of an Alloresponse: Graft-Versus-Tumor, Journal of Hematotherapy & Stem Cell Research, 9, 3, 2000. Crossref
-
Tang Choon-Kit, Apostolopoulos Vasso, Strategies used for MUC1 immunotherapy: preclinical studies, Expert Review of Vaccines, 7, 7, 2008. Crossref
-
Cho Jung-Ah, Yeo Dong-jun, Son Hye-Youn, Kim Hyun-Wha, Jung Dae-Sun, Ko Jae-Kyun, Koh Jason Soonju, Kim Yong-Nyun, Kim Chul-Woo, Exosomes: A new delivery system for tumor antigens in cancer immunotherapy, International Journal of Cancer, 114, 4, 2005. Crossref
-
STEINER MITCHELL S., GINGRICH JEFFREY R., GENE THERAPY FOR PROSTATE CANCER: WHERE ARE WE NOW?, The Journal of Urology, 2000. Crossref
-
Wilkinson Brendan L., Day Stephanie, Chapman Robert, Perrier Sébastien, Apostolopoulos Vasso, Payne Richard J., Synthesis and Immunological Evaluation of Self-Assembling and Self-Adjuvanting Tricomponent Glycopeptide Cancer-Vaccine Candidates, Chemistry - A European Journal, 18, 51, 2012. Crossref
-
Lewis A.T., Jones K., Lewis K.E., Jones S., Lewis P.D., Detection of Lewis antigen structural change by FTIR spectroscopy, Carbohydrate Polymers, 92, 2, 2013. Crossref
-
Bilusic Marijo, Madan Ravi A., Therapeutic Cancer Vaccines, American Journal of Therapeutics, 19, 6, 2012. Crossref
-
Slovin Susan F, Keding Stacy J, Ragupathi Govind, Carbohydrate vaccines as immunotherapy for cancer, Immunology & Cell Biology, 83, 4, 2005. Crossref
-
Sheng Kuo-Ching, Pouniotis Dodie S., Wright Mark D., Tang Choon Kit, Lazoura Eliada, Pietersz Geoffrey A., Apostolopoulos Vasso, Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells, Immunology, 118, 3, 2006. Crossref
-
Barchi Joseph J., Mucin-Type Glycopeptide Structure in Solution: Past, Present, and Future, Biopolymers, 99, 10, 2013. Crossref
-
LaRue Hélène, Parent-Vaugeois Carmen, Bergeron Alain, Champetier and Serge, Fradet Yves, Influence of spatial configuration on the expression of carcinoembryonic antigen and mucin antigens in human bladder cancer, International Journal of Cancer, 71, 6, 1997. Crossref
-
Akashi Hirofumi, Hinoda Yuji, Itoh Fumio, Adachi Masaaki, Endo Takao, Imai Kohzoh, A novel gastric-cancer-associated mucin antigen defined by a monoclonal antibody A3D4, International Journal of Cancer, 73, 6, 1997. Crossref
-
Lazoura Eliada, Lodding Jodie, Farrugia William, Day Stephanie, Ramsland Paul A., Apostolopoulos Vasso, Non-canonical anchor motif peptides bound to MHC class I induce cellular responses, Molecular Immunology, 46, 6, 2009. Crossref
-
Wang Yu-Qian, Zhang Hai-Hong, Liu Chen-Lu, Xia Qiu, Wu Hui, Yu Xiang-Hui, Kong Wei, Correlation Between Auto-antibodies to Survivin and MUC1 Variable Number Tandem Repeats in Colorectal Cancer, Asian Pacific Journal of Cancer Prevention, 13, 11, 2012. Crossref
-
KIEBER-EMMONS THOMAS, LUO PING, QIU JIANPING, AGADJANYAN MICHAEL, CAREY LISA, HUTCHINS WENDY, WESTERINK M.A. JULIE, STEPLEWSKI ZENON, Peptide Mimicry of Adenocarcinoma-Associated Carbohydrate Antigens, Hybridoma, 16, 1, 1997. Crossref
-
Schuman J., Campbell A.P., Koganty R.R., Longenecker B.M., Probing the conformational and dynamical effects of O-glycosylation within the immunodominant region of a MUC1 peptide tumor antigen, The Journal of Peptide Research, 61, 3, 2008. Crossref
-
Wierecky J., Mueller M., Brossart P., Dendritic cell-based cancer immunotherapy targeting MUC-1, Cancer Immunology, Immunotherapy, 55, 1, 2006. Crossref
-
Gul’ko L. B., Pavlova O. V., D’yakov N. A., Okorokova N. A., Ratmanova K. I., Logunova N. N., Bobreneva R. A., Makarov V. A., Yurin V. L., Veiko V. P., Debabov V. G., Construction of a gene of the human tumor-associated antigen VNTR(MUC1) bound to streptavidin, its expression inEscherichia coli, and the study of properties of the hybrid protein, Russian Journal of Bioorganic Chemistry, 26, 6, 2000. Crossref
-
Wurz Gregory T, Kao Chiao-Jung, Wolf Michael, DeGregorio Michael W, Tecemotide: An antigen-specific cancer immunotherapy, Human Vaccines & Immunotherapeutics, 10, 11, 2014. Crossref
-
Rachagani Satyanarayana, Torres Maria P., Moniaux Nicolas, Batra Surinder K., Current status of mucins in the diagnosis and therapy of cancer, BioFactors, 35, 6, 2009. Crossref
-
TROY A.J., HART D.N.J., Review: Dendritic Cells and Cancer: Progress Toward a New Cellular Therapy, Journal of Hematotherapy, 6, 6, 1997. Crossref
-
Kieber-Emmons Thomas, Peptide mimotopes of carbohydrate antigens, Immunologic Research, 17, 1-2, 1998. Crossref
-
Zilberberg Jenny, Feinman Rena, Korngold Robert, Strategies for the Identification of T Cell–Recognized Tumor Antigens in Hematological Malignancies for Improved Graft-versus-Tumor Responses after Allogeneic Blood and Marrow Transplantation, Biology of Blood and Marrow Transplantation, 21, 6, 2015. Crossref
-
Lu Yi, Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer, Advanced Drug Delivery Reviews, 61, 7-8, 2009. Crossref
-
Mittendorf Elizabeth A., Gurney Jennifer M., Storrer Catherine E., Shriver Craig D., Ponniah Sathibalan, Peoples George E., Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer, Surgery, 139, 3, 2006. Crossref
-
Persson Jonas, Ohlin Mats, Antigens for the selection of pan-variable number of tandem repeats motif-specific human antibodies against Mucin-1, Journal of Immunological Methods, 316, 1-2, 2006. Crossref
-
Kaminski Joseph M, Summers James B, Ward Matthew B, Huber Mark R, Minev Boris, Immunotherapy and prostate cancer, Cancer Treatment Reviews, 29, 3, 2003. Crossref
-
Tait Brian D, HLA class I expression on human cancer cells, Human Immunology, 61, 2, 2000. Crossref
-
STEINER MITCHELL S., GINGRICH JEFFREY R., GENE THERAPY FOR PROSTATE CANCER: WHERE ARE WE NOW?, Journal of Urology, 164, 4, 2000. Crossref
-
Martínez Isidoro, Melero José A., Binding of human respiratory syncytial virus to cells: implication of sulfated cell surface proteoglycans, Journal of General Virology , 81, 11, 2000. Crossref
-
Minev Boris R., Chavez Frances L., Mitchell Malcolm S., Cancer Vaccines, Pharmacology & Therapeutics, 81, 2, 1999. Crossref
-
Avichezer Dody, Arnon Ruth, Differential reactivities of theArachis hypogaea(peanut) andVicia villosaB4 lectins with human ovarian carcinoma cells, grown either in vitro or in vivo xenograft model, FEBS Letters, 395, 2-3, 1996. Crossref
-
Slovin Susan F., VACCINES AS TREATMENT STRATEGIES FOR RELAPSED PROSTATE CANCER, Hematology/Oncology Clinics of North America, 15, 3, 2001. Crossref
-
Zöller Margot, Matzku Siegfried, Cancer Therapy: New Concepts on Active Immunization, Immunobiology, 201, 1, 1999. Crossref
-
Martínez Isidoro, Melero José A., A model for the generation of multiple A to G transitions in the human respiratory syncytial virus genome: predicted RNA secondary structures as substrates for adenosine deaminases that act on RNA, Journal of General Virology , 83, 6, 2002. Crossref
-
Roy René, Baek Myung-Gi, Glycodendrimers: novel glycotope isosteres unmasking sugar coding. Case study with T-antigen markers from breast cancer MUC1 glycoprotein, Reviews in Molecular Biotechnology, 90, 3-4, 2002. Crossref
-
Vaughan Hilary A, Ho Deborah W.M, Karanikas Vaios A, Ong Chin-Swee, Hwang Le Ann, Pearson Julian M, McKenzie Ian F.C, Pietersz Geoffrey A, Induction of humoral and cellular responses in cynomolgus monkeys immunised with mannan–human MUC1 conjugates, Vaccine, 17, 20-21, 1999. Crossref
-
Pietersz Geoffrey A, Li Wenjun, Osinski Carla, Apostolopoulos Vasso, McKenzie Ian F.C, Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1, Vaccine, 18, 19, 2000. Crossref
-
Vaughan Hilary A, Ho Deborah W.M, Karanikas Vaios, Sandrin Mauro S, McKenzie Ian F.C, Pietersz Geoffrey A, The immune response of mice and cynomolgus monkeys to macaque mucin 1-mannan, Vaccine, 18, 28, 2000. Crossref
-
Lemieux George A, Bertozzi Carolyn R, Modulating cell surface immunoreactivity by metabolic induction of unnatural carbohydrate antigens, Chemistry & Biology, 8, 3, 2001. Crossref
-
Yuan Shifang, Shi Changhong, Liu Li, Han Wei, MUC1-based recombinant Bacillus Calmette–Guerin vaccines as candidates for breast cancer immunotherapy, Expert Opinion on Biological Therapy, 10, 7, 2010. Crossref
-
Newman Kimberley D., Sosnowski Deborah L., Kwon Glen S., Samuel John, Delivery of MUC1 Mucin Peptide by Poly(d,l-lactic-co-Glycolic Acid) Microspheres Induces type 1T Helper Immune Responses, Journal of Pharmaceutical Sciences, 87, 11, 1998. Crossref
-
Kovjazin Riva, Horn Galit, Smorodinsky Nechama I., Shapira Michael Y., Carmon Lior, Dübel Stefan, Cell Surface-Associated Anti-MUC1-Derived Signal Peptide Antibodies: Implications for Cancer Diagnostics and Therapy, PLoS ONE, 9, 1, 2014. Crossref
-
Shi Lei, Cai Hui, Huang Zhi-Hua, Sun Zhan-Yi, Chen Yong-Xiang, Zhao Yu-Fen, Kunz Horst, Li Yan-Mei, Synthetic MUC1 Antitumor Vaccine Candidates with Varied Glycosylation Pattern BearingR/S-configured Pam3CysSerLys4, ChemBioChem, 17, 15, 2016. Crossref
-
Gray H. J., Benigno B., Berek J., Chang J., Mason J., Mileshkin L., Mitchell P., Moradi M., Recio F. O., Michener C. M., Secord A. Alvarez, Tchabo N E., Chan J. K., Young J., Kohrt H., Gargosky S. E., Goh J. C., Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial, Journal for ImmunoTherapy of Cancer, 4, 1, 2016. Crossref
-
Marcos Nuno T., Cruz Andrea, Silva Filipe, Almeida Raquel, David Leonor, Mandel Ulla, Clausen Henrik, Mensdorff-Pouilly Silvia von, Reis Celso A., Polypeptide GalNAc-transferases, ST6GalNAc-transferase I, and ST3Gal-transferase I Expression in Gastric Carcinoma Cell Lines, Journal of Histochemistry & Cytochemistry, 51, 6, 2003. Crossref
-
Wurz Gregory T., Kao Chiao-Jung, DeGregorio Michael W., Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential, Therapeutic Advances in Medical Oncology, 8, 1, 2016. Crossref
-
Carraway Kermit L., Price-Schiavi Shari A., Zhu Xiaoyun, Komatsu Masanobu, 3. Membrane Mucins and Breast Cancer, Cancer Control, 6, 6, 1999. Crossref
-
KOVJAZIN RIVA, DUBNIK ANNA, HORN GALIT, SMORODINSKY NECHAMA I., HARDAN IZHAR, SHAPIRA MICHAEL YECHIEL, CARMON LIOR, Autoantibodies against the signal peptide domain of MUC1 in patients with multiple myeloma: Implications for disease diagnosis and prognosis, Experimental and Therapeutic Medicine, 3, 6, 2012. Crossref
-
Cao Yi, Blohm Dietmar, Ghadimi B. Michael, Stosiek Peter, Xing Pei-Xiang, Karsten Uwe, Mucins (MUC1 and MUC3) of Gastrointestinal and Breast Epithelia Reveal Different and Heterogeneous Tumor-associated Aberrations in Glycosylation, Journal of Histochemistry & Cytochemistry, 45, 11, 1997. Crossref
-
Dhanisha Suresh Sulekha, Guruvayoorappan Chandrasekharan, Drishya Sudarsanan, Abeesh Prathapan, Mucins: Structural diversity, biosynthesis, its role in pathogenesis and as possible therapeutic targets, Critical Reviews in Oncology/Hematology, 122, 2018. Crossref
-
Cane Patricia A., Respiratory Syncytial Virus, in The Molecular Epidemiology of Human Viruses, 2002. Crossref
-
Quaranta M., Coviello M., Daniele A., Abbate I., Durrant L.G., Paradiso A., Schittulli F., MUC3 and MCA Serum Levels and Steroid Receptor Content in Breast Cancer, The International Journal of Biological Markers, 19, 2, 2004. Crossref
-
Offner Sonja, Hekele Armin, Teichmann Ulrike, Weinberger Susanne, Gross Susanne, Kufer Peter, Itin Christian, Baeuerle Patrick A., Kohleisen Birgit, Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy, Cancer Immunology, Immunotherapy, 54, 5, 2005. Crossref
-
Brossart Peter, Wirths Stefan, Stuhler Gernot, Reichardt Volker L., Kanz Lothar, Brugger Wolfram, Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells, Blood, 96, 9, 2000. Crossref
-
Brossart Peter, Wirths Stefan, Stuhler Gernot, Reichardt Volker L., Kanz Lothar, Brugger Wolfram, Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells, Blood, 96, 9, 2000. Crossref
-
Matzku Siegfried, Z??ller Margot, Specific Immunotherapy of Cancer in Elderly Patients, Drugs & Aging, 18, 9, 2001. Crossref
-
Laheru Dan, Biedrzycki Barbara, Jaffee Elizabeth M., Development of a Cytokine-Modified Allogeneic Whole Cell Pancreatic Cancer Vaccine, in Pancreatic Cancer, 980, 2013. Crossref
-
Roy René, Recent developments in the rational design of multivalent glycoconjugates, in Glycoscience Synthesis of Substrate Analogs and Mimetics, 187, 1997. Crossref
-
Janda K. D., New Directions in Immunopharmacotherapy, in The Role of Natural Products in Drug Discovery, 2000. Crossref
-
Barriga Vanessa, Kuol Nyanbol, Nurgali Kulmira, Apostolopoulos Vasso, The Complex Interaction between the Tumor Micro-Environment and Immune Checkpoints in Breast Cancer, Cancers, 11, 8, 2019. Crossref
-
Hart Derek N.J., Dendritic Cells: Unique Leukocyte Populations Which Control the Primary Immune Response, Blood, 90, 9, 1997. Crossref
-
Brossart Peter, Heinrich Kathrin S., Stuhler Gernot, Behnke Lars, Reichardt Volker L., Stevanovic Stefan, Muhm Alexandra, Rammensee Hans-Georg, Kanz Lothar, Brugger Wolfram, Identification of HLA-A2–Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies, Blood, 93, 12, 1999. Crossref
-
Brossart Peter, Heinrich Kathrin S., Stuhler Gernot, Behnke Lars, Reichardt Volker L., Stevanovic Stefan, Muhm Alexandra, Rammensee Hans-Georg, Kanz Lothar, Brugger Wolfram, Identification of HLA-A2–Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies, Blood, 93, 12, 1999. Crossref
-
Fini M. Elizabeth, Jeong Shinwu, Gong Haiyan, Martinez-Carrasco Rafael, Laver Nora M.V., Hijikata Minako, Keicho Naoto, Argüeso Pablo, Membrane-associated mucins of the ocular surface: New genes, new protein functions and new biological roles in human and mouse, Progress in Retinal and Eye Research, 75, 2020. Crossref
-
Le Dung, Jaffee Elizabeth M., Laheru Dan, Development of Vaccine Therapy for Pancreas Cancer, in Pancreatic Cancer, 2008. Crossref
-
González-Mariscal Lorenza, Díaz-Coránguez Mónica, Quirós Miguel, Regulation of Tight Junctions for Therapeutic Advantages, in Tight Junctions in Cancer Metastasis, 19, 2013. Crossref
-
O’Reilly Eileen M., Vaccine Therapy for Pancreatic Cancer, in Pancreatic Cancer, 2002. Crossref
-
Gao Tong, Cen Qianhong, Lei Han, A review on development of MUC1-based cancer vaccine, Biomedicine & Pharmacotherapy, 132, 2020. Crossref
-
Bergeron Alain, Champetier Serge, LaRue Hélène, Fradet Yves, MAUB Is a New Mucin Antigen Associated with Bladder Cancer , Journal of Biological Chemistry, 271, 12, 1996. Crossref
-
Lee Dong-Hee, Choi Seunghyun, Park Yoon, Jin Hyung-seung, Mucin1 and Mucin16: Therapeutic Targets for Cancer Therapy, Pharmaceuticals, 14, 10, 2021. Crossref
-
Laheru Dan, Lutz Eric, Burke James, Biedrzycki Barbara, Solt Sara, Onners Beth, Tartakovsky Irena, Nemunaitis John, Le Dung, Sugar Elizabeth, Hege Kristen, Jaffee Elizabeth, Allogeneic Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation, Clinical Cancer Research, 14, 5, 2008. Crossref
-
Müller Stefan, Hanisch Franz-Georg, Recombinant MUC1 Probe Authentically Reflects Cell-specific O-Glycosylation Profiles of Endogenous Breast Cancer Mucin, Journal of Biological Chemistry, 277, 29, 2002. Crossref
-
Fong C L, Mok C-L, Hui K M, Intramuscular immunization with plasmid coexpressing tumour antigen and Flt-3L results in potent tumour regression, Gene Therapy, 13, 3, 2006. Crossref
-
Bourgeois C., Bour J. B., Lidholt K., Gauthray C., Pothier P., Heparin-Like Structures on Respiratory Syncytial Virus Are Involved in Its Infectivity In Vitro, Journal of Virology, 72, 9, 1998. Crossref
-
Gerken Thomas A., Owens Cheryl L., Pasumarthy Murali, Site-specific Core 1 O-Glycosylation Pattern of the Porcine Submaxillary Gland Mucin Tandem Repeat, Journal of Biological Chemistry, 273, 41, 1998. Crossref
-
Mao Shenlan, Gao Changshou, Lo Chih-Hung L., Wirsching Peter, Wong Chi-Huey, Janda Kim D., Phage-display library selection of high-affinity human single-chain antibodies to tumor-associated carbohydrate antigens sialyl Lewis x and Lewis x , Proceedings of the National Academy of Sciences, 96, 12, 1999. Crossref
-
Medarova Zdravka, Rashkovetsky Leonid, Pantazopoulos Pamela, Moore Anna, Multiparametric Monitoring of Tumor Response to Chemotherapy by Noninvasive Imaging, Cancer Research, 69, 3, 2009. Crossref
-
Li Zhifeng, Yang Dazhuang, Guo Ting, Lin Mei, Advances in MUC1-Mediated Breast Cancer Immunotherapy, Biomolecules, 12, 7, 2022. Crossref
-
Ephraim Ramya, Fraser Sarah, Nurgali Kulmira, Apostolopoulos Vasso, Checkpoint Markers and Tumor Microenvironment: What Do We Know?, Cancers, 14, 15, 2022. Crossref
-
Apostolopoulos Vasso, Stojanovska Lily, Gargosky Sharron E., MUC1 (CD227): a multi-tasked molecule, Cellular and Molecular Life Sciences, 72, 23, 2015. Crossref
-
Freire Teresa, Landeira Mercedes, Giacomini Cecilia, Festari María Florencia, Pittini Álvaro, Cardozo Viviana, Brosque Alina, Monin Leticia, da Costa Valeria, Faral-Tello Paula, Robello Carlos, Osinaga Eduardo, Trypanosoma cruzi-Derived Molecules Induce Anti-Tumour Protection by Favouring Both Innate and Adaptive Immune Responses, International Journal of Molecular Sciences, 23, 23, 2022. Crossref